{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:34:56Z","timestamp":1783406096792,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001671","name":"Hereditary Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000887","name":"Huntington's Disease Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Wellcome\/EPSRC Centre for Medical Engineering [WT 203148\/Z\/16\/Z]"],"award-info":[{"award-number":["Wellcome\/EPSRC Centre for Medical Engineering [WT 203148\/Z\/16\/Z]"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Wellcome Collaborative Award in Science 200181\/Z\/1"],"award-info":[{"award-number":["Wellcome Collaborative Award in Science 200181\/Z\/1"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["EMIF grant"],"award-info":[{"award-number":["EMIF grant"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish State Support for Clinical Research"},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffman-La Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Brain-derived neurotrophic factor (BDNF) is implicated in the survival of striatal neurons. BDNF function is reduced in Huntington\u2019s disease (HD), possibly because mutant huntingtin impairs its cortico-striatal transport, contributing to striatal neurodegeneration. The BDNF trophic pathway is a therapeutic target, and blood BDNF has been suggested as a potential biomarker for HD, but BDNF has not been quantified in cerebrospinal fluid (CSF) in HD. We quantified BDNF in CSF and plasma in the HD-CSF cohort (20 pre-manifest and 40 manifest HD mutation carriers and 20 age and gender-matched controls) using conventional ELISAs and an ultra-sensitive immunoassay. BDNF concentration was below the limit of detection of the conventional ELISAs, raising doubt about previous CSF reports in neurodegeneration. Using the ultra-sensitive method, BDNF concentration was quantifiable in all samples but did not differ between controls and HD mutation carriers in CSF or plasma, was not associated with clinical scores or MRI brain volumetric measures, and had poor ability to discriminate controls from HD mutation carriers, and premanifest from manifest HD. We conclude that BDNF in CSF and plasma is unlikely to be a biomarker of HD progression and urge caution in interpreting studies where conventional ELISA was used to quantify CSF BDNF.<\/jats:p>","DOI":"10.1038\/s41598-021-83000-x","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T17:27:28Z","timestamp":1612978048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Zhen-Yi Andy","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Tortelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileanoir B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha S.","family":"Foiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Arridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael I.","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"83000_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mdc3.12502","volume":"4","author":"FB Rodrigues","year":"2017","unstructured":"Rodrigues, F. B. et al. Survival, mortality, causes and places of death in a European Huntington\u2019s disease prospective cohort. Mov. Disord. Clin. Pract. 4, 737\u2013742 (2017).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"83000_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato, C. et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science 293, 493\u2013498 (2001).","journal-title":"Science"},{"key":"83000_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0006-8993(00)02237-X","volume":"866","author":"I Ferrer","year":"2000","unstructured":"Ferrer, I., Goutan, E., Marin, C., Rey, M. & Ribalta, T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 866, 257\u2013261 (2000).","journal-title":"Brain Res."},{"key":"83000_CR4","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1523\/JNEUROSCI.5100-09.2010","volume":"30","author":"S Rauskolb","year":"2010","unstructured":"Rauskolb, S. et al. Global deprivation of brain-derived neurotrophic factor in the CNS reveals an area-specific requirement for dendritic growth. J. Neurosci. 30, 1739\u20131749 (2010).","journal-title":"J. Neurosci."},{"key":"83000_CR5","doi-asserted-by":"publisher","first-page":"11758","DOI":"10.1523\/JNEUROSCI.2461-07.2007","volume":"27","author":"AD Strand","year":"2007","unstructured":"Strand, A. D. et al. Expression profiling of Huntington\u2019s disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 27, 11758\u201311768 (2007).","journal-title":"J. Neurosci."},{"key":"83000_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.nbd.2015.08.008","volume":"82","author":"Q Ma","year":"2015","unstructured":"Ma, Q., Yang, J., Li, T., Milner, T. A. & Hempstead, B. L. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington\u2019s disease. Neurobiol. Dis. 82, 466\u2013477 (2015).","journal-title":"Neurobiol. Dis."},{"key":"83000_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","volume":"105","author":"K Gharami","year":"2008","unstructured":"Gharami, K., Xie, Y., An, J. J., Tonegawa, S. & Xu, B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington\u2019s disease phenotypes in mice. J. Neurochem. 105, 369\u2013379 (2008).","journal-title":"J. Neurochem."},{"key":"83000_CR8","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.1523\/JNEUROSCI.4278-06.2007","volume":"26","author":"C Zuccato","year":"2007","unstructured":"Zuccato, C. et al. Widespread disruption of repressor element-1 silencing transcription factor\/neuron-restrictive silencer factor occupancy at its target genes in Huntington\u2019s disease. J. Neurosci. 26, 6972\u20136983 (2007).","journal-title":"J. Neurosci."},{"key":"83000_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier, L. R. et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127\u2013138 (2004).","journal-title":"Cell"},{"key":"83000_CR10","doi-asserted-by":"publisher","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Y Xie","year":"2010","unstructured":"Xie, Y., Hayden, M. R. & Xu, B. BDNF overexpression in the forebrain rescues Huntington\u2019s Disease phenotypes in YAC128 Mice. J. Neurosci. 30, 14708\u201314718 (2010).","journal-title":"J. Neurosci."},{"key":"83000_CR11","doi-asserted-by":"publisher","first-page":"e87923","DOI":"10.1371\/journal.pone.0087923","volume":"9","author":"D Todd","year":"2014","unstructured":"Todd, D. et al. A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington\u2019s disease. PLoS ONE 9, e87923 (2014).","journal-title":"PLoS ONE"},{"key":"83000_CR12","doi-asserted-by":"publisher","first-page":"e907","DOI":"10.1038\/tp.2016.186","volume":"6","author":"SS Jiao","year":"2016","unstructured":"Jiao, S. S. et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer\u2019s disease. Transl. Psychiatry 6, e907 (2016).","journal-title":"Transl. Psychiatry"},{"key":"83000_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00415-009-5357-2","volume":"257","author":"P Scalzo","year":"2010","unstructured":"Scalzo, P., K\u00fcmmer, A., Bretas, T. L., Cardoso, F. & Teixeira, A. L. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson\u2019s disease. J. Neurol. 257, 540\u2013545 (2010).","journal-title":"J. Neurol."},{"key":"83000_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1755-5949.2008.00068.x","volume":"15","author":"F Squitieri","year":"2009","unstructured":"Squitieri, F. et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington\u2019s disease. CNS Neurosci. Ther. 15, 1\u201311 (2009).","journal-title":"CNS Neurosci. Ther."},{"key":"83000_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1055\/s-0037-1613072","volume":"87","author":"H Fujimura","year":"2002","unstructured":"Fujimura, H. et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb. Haemost. 87, 728\u2013734 (2002).","journal-title":"Thromb. Haemost."},{"key":"83000_CR16","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1523\/JNEUROSCI.5599-03.2004","volume":"24","author":"GJ Burbach","year":"2004","unstructured":"Burbach, G. J. et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J. Neurosci. 24, 2421\u20132430 (2004).","journal-title":"J. Neurosci."},{"key":"83000_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000324327","volume":"65","author":"M Kizawa-Ueda","year":"2011","unstructured":"Kizawa-Ueda, M. et al. Neurotrophin levels in cerebrospinal fluid of adult patients with meningitis and encephalitis. Eur. Neurol. 65, 138\u2013143 (2011).","journal-title":"Eur. Neurol."},{"key":"83000_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jpsychires.2006.01.014","volume":"41","author":"C Laske","year":"2007","unstructured":"Laske, C. et al. BDNF serum and CSF concentrations in Alzheimer\u2019s disease, normal pressure hydrocephalus and healthy controls. J. Psychiatr. Res. 41, 387\u2013394 (2007).","journal-title":"J. Psychiatr. Res."},{"key":"83000_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","volume":"1780","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues, F. B., Byrne, L. M. & Wild, E. J. Biofluid biomarkers in Huntington\u2019s disease. Methods Mol. Biol. 1780, 329\u2013396 (2018).","journal-title":"Methods Mol. Biol."},{"key":"83000_CR20","first-page":"728","volume":"87","author":"LM Byrne","year":"2018","unstructured":"Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci. Transl. Med. 87, 728\u2013734 (2018).","journal-title":"Sci. Transl. Med."},{"key":"83000_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov. Disord. 11, 136\u2013142 (1996).","journal-title":"Mov. Disord."},{"key":"83000_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.abc2888","volume":"12","author":"FB Rodrigues","year":"2020","unstructured":"Rodrigues, F. B.\u00a0et al.\u00a0Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington\u2019s disease.\u00a0Sci. Transl. Med. 12, 1\u201313\u00a0(2020).","journal-title":"Sci. Transl. Med."},{"key":"83000_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-45976-5","volume":"9","author":"AK Gejl","year":"2019","unstructured":"Gejl, A. K. et al. Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci. Rep. 9, 1\u20139 (2019).","journal-title":"Sci. Rep."},{"key":"83000_CR24","doi-asserted-by":"publisher","first-page":"e39358","DOI":"10.1371\/journal.pone.0039358","volume":"7","author":"A Pillai","year":"2012","unstructured":"Pillai, A. et al. Plasma BDNF levels vary in relation to body weight in females. PLoS ONE 7, e39358 (2012).","journal-title":"PLoS ONE"},{"key":"83000_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00421-010-1658-5","volume":"111","author":"SH Jung","year":"2011","unstructured":"Jung, S. H., Kim, J., Davis, J. M., Blair, S. N. & Cho, H. C. Association among basal serum BDNF, cardiorespiratory fitness and cardiovascular disease risk factors in untrained healthy Korean men. Eur. J. Appl. Physiol. 111, 303\u2013311 (2011).","journal-title":"Eur. J. Appl. Physiol."},{"key":"83000_CR26","doi-asserted-by":"publisher","first-page":"e5424","DOI":"10.1371\/journal.pone.0005424","volume":"4","author":"G Li","year":"2009","unstructured":"Li, G. et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS ONE 4, e5424 (2009).","journal-title":"PLoS ONE"},{"key":"83000_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neurobiolaging.2004.03.002","volume":"26","author":"M Lommatzsch","year":"2005","unstructured":"Lommatzsch, M. et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol. Aging 26, 115\u2013123 (2005).","journal-title":"Neurobiol. Aging"},{"key":"83000_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne, L. M. et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol. 16, 601\u2013609 (2017).","journal-title":"Lancet Neurol."},{"key":"83000_CR29","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/npp.2015.349","volume":"41","author":"KR Maynard","year":"2016","unstructured":"Maynard, K. R. et al. Functional role of BDNF production from unique promoters in aggression and serotonin signaling. Neuropsychopharmacology 41, 1943\u20131955 (2016).","journal-title":"Neuropsychopharmacology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83000-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83000-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83000-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T22:36:05Z","timestamp":1670020565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83000-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83000"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83000-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.02.20222166","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"17 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZAO, LMB, FBR, MF, RT, EBJ, RIS, AH, HZ, EJW are University College London employees. MA is a University College London Hospitals NHS Foundation Trust employee. EDV is a King\u2019s College London employee. LMR has provided consultancy services to GLG, F. Hoffmann-La Roche Ltd, Genentech and Annexon. FBR has provided consultancy services to GLG and F. Hoffmann-La Roche Ltd. RIS has undertaken consultancy services for Ixitech Ltd. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). EJW reports grants from Medical Research Council, CHDI Foundation, and F. Hoffmann-La Roche Ltd during the conduct of the study; personal fees from Hoffman La Roche Ltd, Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda and Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3481"}}